Merck, Pfizer Decorate Consumer Health 'For Sale' Signs With Strong Results

Merck KGAA reports 11% growth in sales of its OTC lines over a year ago, but, like Pfizer, looks to sharpen its long-term focus on the Rx business.

The two major pharmaceutical firms shopping their consumer health assets are reporting growth in the sector, supporting their pitches that the businesses are strong and could grow faster elsewhere but are on the block because they don't align with the firms' long-term outlooks.

Merck KGAAand Pfizer Inc.are looking for potential buyers for their OTC drug and dietary supplement businesses or for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from International

More from Geography